BITOC
Biotron Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Biotron Limited - Option Expiring 25-Nov-2024
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BITOC
5
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in BITOC
512 days
BITOC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
17%
50k - 100k
17%
Less than 50k
67%
👶 Age of investors
18 - 25
26 - 34
20%
35 - 90
80%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in BITOC also invest in...
Renascor Resources Ltd. engages in the exploration and evaluation of mineral property. The company is headquartered in Adelaide, South Australia. The company went IPO on 2010-12-15. The Company’s projects include Siviour Battery Anode Materials, Carnding Gold, Marree, Olary and Eastern Eyre. The Carnding Project contains several near-surface, high-grade gold prospects (up to 16 g/t from previous drilling) in South Australia’s Central Gawler Craton. At Carnding, the Company is targeting shallow, high-grade gold occurrences. Within the project area, the Company has identified multiple high priority gold targets based on shallow drilling. The Marree Project is a copper-prospective ground position within South Australia’s Adelaide Fold Belt. Its exploration program is focused on identifying and drilling prospects for large tonnage Zambian Copper Belt-style, sedimentary copper deposits. The company holds interest in Marree Project exploration licenses, EL 6170 and EL 6403.
📊 Share price
$0.20 AUD
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The firm is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. The company also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.
📊 Share price
$0.03 AUD
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its HER-Vaxx is a B-cell immuno-therapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. PD1-Vaxx is a B-cell immuno-therapy, which aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer. Its clinical trial candidates include VAXINIA, CHECKvacc, B-Vaxx and others. Its platform technologies seek to harness the body’s immune system against tumors.
📊 Share price
$0.11 AUD
NULL HEALTH
VHY.AX was created on 2011-05-26 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax.
📊 Share price
$66.86 AUD
NULL AUSTRALIA
NULL BETA
NULL INCOME
Want more shares? Try these...
Booktopia Group Ltd. operates an online bookstore. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-03. The firm sells electronic books (e-books), digital versatile discs (DVD), audiobooks, magazines and stationery. Its brands include Booktopia, Booktopia Publisher Services (BPS) and Booktopia Publishing. BPS offers publishers with distribution solutions to the Australian and New Zealand market. Booktopia Publishing is its trade publishing division that publishes books in print and digital formats under the Booktopia Editions imprint. The company offers books of various subjects and topics, which includes Australian Fiction, classic fiction, crime & mystery, historical, poetry, science fiction, thrillers & mystery and more. The company serves corporate and government customers, including schools, libraries, universities and government departments. Its customer fulfilment center (CFC) is located in Lidcombe, Western Sydney. Its subsidiaries include Booktopia Pty Ltd, Making IT Better Pty Ltd and Virtual Lifestyles Pty Ltd.
📊 Share price
$0.20 AUD
BKI Investment Company Ltd is a AU-based company operating in industry. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2003-12-12. BKI Investment Company Limited is an Australia-based investment company. The firm is primarily focused on long term investments in Australian Securities Exchange (ASX) listed securities. The firm focuses on generating an increasing income stream for distribution to shareholders in the form of fully franked dividends to the extent of available imputation tax credits, through long-term investment in a portfolio of assets that are also able to deliver long term capital growth to shareholders. Its investment strategy is focused on research-driven, active equities management, investing for the long term, in profitable companies that pay attractive dividend yields. The firm's portfolio includes sectors, such as financials, materials, energy, consumer discretionary, utilities, industrials, consumer staples, telecommunication services, healthcare and property. Its investment manager is Contact Asset Management Pty Limited.
📊 Share price
$1.71 AUD
NULL AUSTRALIA
NULL ACTIVE
NULL BETA
Bisalloy Steel Group Ltd. engages in the production and sale of bisalloy quenched and tempered steel plate. The company is headquartered in Wollongong, New South Wales. The company went IPO on 2003-06-23. The firm operates through two geographic segments: Australia and Overseas. The Australian operations are comprised of Bisalloy Steels Pty Limited and Bisalloy Steel Group Limited. Bisalloy Steels Pty Limited manufactures and sells wear-grade and high tensile plate through distributors and directly to original equipment manufacturers in both Australia and Overseas. The Overseas operations comprise PT Bima Bisalloy and Bisalloy (Thailand) Co Limited located in Indonesia and Thailand respectively. These businesses distribute Bisalloy Q&T plate as well as other steel plate products. The Overseas operations also include the co-operative joint venture Bisalloy Shangang (Shandong) Steel Plate Co. Limited, which is engaged in marketing, sale and distribution of quench and tempered steel plate.
📊 Share price
$1.93 AUD
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The firm is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. The company also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.
📊 Share price